---
annotation-target: fonc-11-750323.pdf

---


>%%
>```annotation-json
>{"created":"2022-08-08T06:43:28.512Z","text":"奇达胺","updated":"2022-08-08T06:43:28.512Z","document":{"title":"A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China","link":[{"href":"urn:x-pdf:7a528294112740f4483f008d7e304a9a"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf"}],"documentFingerprint":"7a528294112740f4483f008d7e304a9a"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","selector":[{"type":"TextPositionSelector","start":5772,"end":5781},{"type":"TextQuoteSelector","exact":"Chidamide","prefix":"021doi: 10.3389/fonc.2021.750323","suffix":" has demonstrated significant cl"}]}]}
>```
>%%
>*%%PREFIX%%021doi: 10.3389/fonc.2021.750323%%HIGHLIGHT%% ==Chidamide== %%POSTFIX%%has demonstrated significant cl*
>%%LINK%%[[#^8jfm8wyycqo|show annotation]]
>%%COMMENT%%
>奇达胺
>%%TAGS%%
>
^8jfm8wyycqo


>%%
>```annotation-json
>{"created":"2022-08-08T06:43:59.082Z","updated":"2022-08-08T06:43:59.082Z","document":{"title":"A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China","link":[{"href":"urn:x-pdf:7a528294112740f4483f008d7e304a9a"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf"}],"documentFingerprint":"7a528294112740f4483f008d7e304a9a"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","selector":[{"type":"TextPositionSelector","start":5847,"end":5898},{"type":"TextQuoteSelector","exact":"relapsed/refractory (R/R) PTCL in previous studies.","prefix":"ical benefits for patients with ","suffix":" This multi-center observational"}]}]}
>```
>%%
>*%%PREFIX%%ical benefits for patients with%%HIGHLIGHT%% ==relapsed/refractory (R/R) PTCL in previous studies.== %%POSTFIX%%This multi-center observational*
>%%LINK%%[[#^5bw5jd1cv6c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5bw5jd1cv6c


>%%
>```annotation-json
>{"created":"2022-08-08T06:58:29.633Z","updated":"2022-08-08T06:58:29.633Z","document":{"title":"A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China","link":[{"href":"urn:x-pdf:7a528294112740f4483f008d7e304a9a"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf"}],"documentFingerprint":"7a528294112740f4483f008d7e304a9a"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","selector":[{"type":"TextPositionSelector","start":9859,"end":10006},{"type":"TextQuoteSelector","exact":"The response criteria was based on the Lugano classificationrecommendation for response assessment of Hodgkin lymphomaand non-Hodgkin lymphoma (20)","prefix":"according to physicians’choices.","suffix":". ORR was defined as theproporti"}]}]}
>```
>%%
>*%%PREFIX%%according to physicians’choices.%%HIGHLIGHT%% ==The response criteria was based on the Lugano classificationrecommendation for response assessment of Hodgkin lymphomaand non-Hodgkin lymphoma (20)== %%POSTFIX%%. ORR was defined as theproporti*
>%%LINK%%[[#^2qpmtrh82h9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2qpmtrh82h9


>%%
>```annotation-json
>{"created":"2022-08-08T07:03:28.293Z","updated":"2022-08-08T07:03:28.293Z","document":{"title":"A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China","link":[{"href":"urn:x-pdf:7a528294112740f4483f008d7e304a9a"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf"}],"documentFingerprint":"7a528294112740f4483f008d7e304a9a"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-750323.pdf","selector":[{"type":"TextPositionSelector","start":10424,"end":10605},{"type":"TextQuoteSelector","exact":"A chi-square test was usedfor comparison of categorical variables, and a t test was used forcomparison of continuous variables. Kaplan-Meier method wasemployed for survival analysis","prefix":"tware (Version 25.0; IBM Corp). ","suffix":". Multivariate analysis for OS w"}]}]}
>```
>%%
>*%%PREFIX%%tware (Version 25.0; IBM Corp).%%HIGHLIGHT%% ==A chi-square test was usedfor comparison of categorical variables, and a t test was used forcomparison of continuous variables. Kaplan-Meier method wasemployed for survival analysis== %%POSTFIX%%. Multivariate analysis for OS w*
>%%LINK%%[[#^m3hqq8bmboj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^m3hqq8bmboj
